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Abstract
Background and objective: PRECISE is a population-based, prospective pregnancy cohort study designed for deep
phenotyping of pregnancies in women with placenta-related disorders, and in healthy controls. The PRECISE
Network is recruiting ~ 10,000 pregnant women in three countries (The Gambia, Kenya, and Mozambique)
representing sub-Saharan Africa. The principal aim is to improve our understanding of pre-eclampsia, fetal growth
restriction and stillbirth. This involves the creation of a highly curated biorepository for state of the art discovery
science and a rich database of antenatal variables and maternal and neonatal outcomes. Our overarching aim is to
provide large sample numbers with adequate power to address key scientific questions. Here we describe our
experience of establishing a biorepository in the PRECISE Network and review the issues and challenges
surrounding set-up, management and scientific use.
Methods: The feasibility of collecting and processing each sample type was assessed in each setting and plans
made for establishing the necessary infrastructure. Quality control (QC) protocols were established to ensure that
biological samples are ‘fit-for-purpose'. The management structures required for standardised sample collection and
processing were developed. This included the need for transport of samples between participating countries and to
external academic/commercial institutions.
Results: Numerous practical challenges were encountered in setting up the infrastructure including facilities,
staffing, training, cultural barriers, procurement, shipping and sample storage. Whilst delaying the project, these
were overcome by establishing good communication with the sites, training workshops and constant engagement
with the necessary commercial suppliers. A Project Executive Committee and Biology Working Group together
defined the biospecimens required to answer the research questions paying particular attention to harmonisation
of protocols with other cohorts so as to enable cross-biorepository collaboration. Governance structures
implemented include a Data and Sample Committee to ensure biospecimens and data will be used according to
consent, and prioritisation by scientific excellence. A coordinated sample and data transfer agreement will prevent
delay in sample sharing.
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Discussion: With adequate training and infrastructure, it is possible to establish high quality sample collections to
facilitate research programmes such as the PRECISE Network in sub-Saharan Africa. These preparations are pre-
requisites for effective execution of a biomarker-based approach to better understand the complexities of placental
disease in these settings, and others.
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Introduction
The PRECISE network cohort study
The PRECISE (PREgnancy Care Integrating translational
Science Everywhere) Network has enabled a population-
based, prospective cohort study designed to improve our
understanding of the mechanisms leading towards placen-
tal disease and related pregnancy complications in sub-
Saharan Africa [1]. The cohort study aims to recruit a
total of up to 10,000 pregnant women and, for compari-
son, 1800 non-pregnant women of reproductive age across
the three countries: The Gambia, Kenya and Mozambique.
Biological specimens are being collected longitudinally
across the continuum of pregnancy, delivery, and the neo-
natal period. In addition, sites are consenting women who
present at the health facility with complications during
pregnancy. All sites will collect a comprehensive set of as-
sociated phenotypic information to deeply characterise
these pregnancies [2]. Table 1 describes the cohorts with
expected recruitment per country.
The samples will establish a biorepository which will
be accessible to the PRECISE Network for research to
identify biological markers (e.g., genomic, metagenomic,
proteomic, metabolomic, hormonal and inflammatory)
as predictors of important maternal and fetal outcomes.
Samples remaining after the initial analysis will be avail-
able to other approved researchers to facilitate and ac-
celerate future discoveries on maternal, fetal, and
neonatal health. Another major objective of this study is
to build individual and institutional research capacity
across Africa. The biorepositories will be a significant re-
source for all of Africa [3], enabling ongoing multi-
omics research on pregnancy complications as well as
the developmental origins of health and disease.
Here we describe the methodology applied to setting
up the infrastructure and governance for the develop-
ment of this large biorepository in these sub-Saharan Af-
rican countries.
Methods
Optimal sample collection
To carry out scientific research at the highest standard,
collection and curation of the biorepository has to be
optimised to ensure quality. This requires rigorous pro-
tocols for handling of samples and storage to avoid bio-
logical degradation according to evidence-based best
practice [4]. The PRECISE team, with assistance from an
experienced consultant in this field, adhered to Inter-
national Society for Biological and Environmental Re-
positories (ISBER), NIH, and NCI Best Practices for
establishing and operating biorepositories [5, 6]. This in-
cluded an initial assessment of biobanking capabilities,
including but not limited to, laboratory and storage facil-
ities, IT, staffing, security, and emergency/disaster plan.
PRECISE Standard operating procedures (SOPs) were
Table 1 Recruitment by country and cohort
Country Facility Non-pregnant women
of reproductive age
Unselected Pregnant
Women
Pregnant Women Presenting
with Complications
Total Women
Recruited
The Gambia:
Farafenni District Hospital 600 2000 300 2900
Illiasa, Rural PHC
Ngayen Sanjal Rural PHC
Kenya:
Mariakani Subcounty Hospital 600 4000 600 5200
Rabai Rural Health Centre
Mozambique:
Manhica Tertiary Referral Centre 600 4000 600 5200
Xinavane Rural Hospital
Total 1800 10,000 1500 13,300
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developed for each sample type from collection to final
storage and labelling. The PRECISE SOPs are harmo-
nised with other pregnancy cohort sample collections
across (low- and middle-income countries (LMICs) so
that samples from multiple sites are comparable and
can be pooled for large-scale studies. The SOPs were
translated to the appropriate languages for the sites
and included protocols to control pre-analytical vari-
ables to protect protein, DNA and RNA integrity,
including:
 Avoidance of haemolysis during venepuncture of
blood samples
 Time stamping to document length of time sample
is at room temperature: before processing, and
between processing and placing into storage
 Documenting visual quality of blood derivatives (e.g.,
colour of plasma)
 Continuous monitoring of temperatures of sample
storage units (freezers and liquid nitrogen tanks) to
assure constant optimum temperature
 Documenting calibration of equipment used for
processing and analysing samples
Quality control
A procedure has been established to routinely assess
sample quality. The primary method that PREICSE is
following for quality control is ensuring strict adherence
to the protocol and SOPs. This is accomplished by ex-
tensive training and frequent site visits at the start of
collections to monitor collections and processing as well
as safety. Additionally, the PRECISE coordinator sched-
ules weekly calls with the teams to address any chal-
lenges and to share experiences and learnings.
Best Practices recommends assessing quality of speci-
mens throughout the collection period. As testing quality
means using up valuable resources for research, it was de-
cided to test approximately 2 % of samples from the biore-
source at regular intervals across the length of the project
for quality control checks. The sampling protocol ensures
the numbers tested are adequate to confirm quality but at
the same time avoiding depletion of the bioresource. Sam-
pling is structured to include participants across all sites
for the entire duration of the project.
The PRECISE Network Biorepository Quality Assess-
ment Protocol includes assessment of DNA and RNA
purity and concentration as well as RNA integrity in
blood and tissue samples. For placental histology, PRE-
CISE will use standard haematoxylin- and eosin- (H&E)
stained slides, as well as at least one immunohistochem-
istry marker to check on the viability of the tissues for
antigen retrieval. Table 2 indicates the cut-offs for the
quality standards.
Overview of bioresource protocol
The PRECISE Biology Working Group defined the bios-
pecimen collection framework (Table 3) and the sample
collection protocol (Table 4). Phenotypic data will be
collected at each visit where biospecimens are taken [2].
Biospecimen collection and processing
Maternal and cord blood: A blood spot and aliquots of
whole blood, plasma, buffy coat will be extracted from
blood collected in an EDTA vacutainer. Serum aliquots
will be obtained from blood collected in a siliconized
vacutainer.
Maternal urine: Aliquots of untreated urine and urine
sediment will be stored.
Mid-vaginal swabs: Two swabs for DNA extraction
and sequencing will be immediately placed in Tris-
EDTA (TE) buffer for storage and two additional swabs
will be collected in PBS plus protease inhibitor for bio-
chemical analysis.
Placental, cord and membrane tissue samples: These
samples will be collected and processed within 30min of
delivery (Fig. 1 demonstrates placenta protocol). Full
thickness central and peripheral sampling of the placenta
will be undertaken and samples snap frozen in LN2. Cor-
responding samples will be stored in formalin for hist-
ology. Cord tissue samples will be snap frozen in LN2
and another sample placed in formalin. A fetal mem-
brane sample will retained in formalin for histology.
Photographs and trimmed weight are also acquired and
stored.
Delayed cord blood: In cases where the cord blood is
not available immediately, a sample of the clotted cord
blood will be taken for provision of newborn DNA only.
Newborn heel prick: In the absence of cord blood, a
newborn heel prick blood sample will be taken for a
DNA sample or taken at the 6 week follow-up visit.
Whilst the protocol dictates that specimens are
promptly processed before being placed into aliquots and
short-term storage, practicalities necessitated minor pro-
cedural differences between countries in order to achieve
this. Therefore, in The Gambia and Mozambique, aliquots
will be temporarily stored in LN2 (gas phase) until trans-
ported to the main bioresource facility where they are
transferred to − 80 °C freezers for long-term storage. In
Table 2 Quality Measures for sample RNA, DNA and histology.
RIN (RNA Integrity Number), DIN (DNA Integrity Number), H&E
haematoxylin- and eosin-staining, IHC Immuno-histochemistry
Specimen type Primary Secondary
RNA RIN value ≥7.0 260/280 ratio: 1.9–2.1
DNA DIN value ≥7.0 260/280 ratio: 1.7–1.9
Placenta RIN value ≥7.0 RNA Extraction 260/280 ratio
Placenta Histology H&E IHC Markers e.g. vimentin
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Kenya, samples will be stored immediately in − 80 °C
freezers once processed.
Biorepository governance
Approval for the study, including sample collection and
storage, was obtained from all participating institutions,
hospitals and relevant ethics committees. The principle
of sharing samples between sites was included in the
ethics approval which has been granted in each of the
participating countries. The biorepository samples be-
long to the country of origin and will not be collated
into a central biobank.
A Data and Sample Committee (DSC) has been con-
vened to act as the governing authority of the PRECISE
biorepository and to provide guidance and oversight for
the collection, processing and utilisation of the samples.
The committee is composed of 13 members, six core
members defined by their role in the study and seven
subject matter experts. The core members are the PRE-
CISE Chief Investigator, the Principal Investigator from
each site, chair of the Biospecimen Quality Committee,
and Biorepository Research Co-ordinator (Secretary).
The chair can appoint up to seven knowledgeable ex-
perts and community representatives with special quali-
fications and competence to deal effectively with specific
biorepository or data issues.
The DSC follows a clearly outlined mandate which
includes:
 Providing oversight and assurance of the quality of
samples being collected across three sites. This will
involve reviewing the regular reports from the
Biospecimen Quality Committee and providing
Table 4 Summary of sample types collected in PRECISE
Sample type Collection tube Aliquots Storage
Blood EDTA Blood spot Room temperature
EDTA Whole blood −80 °C
EDTA Buffy coat −80 °C
EDTA Plasma −80 °C
Serum Serum −80 °C
Urine no treatment Urine −80 °C
Urine sediment −80 °C
Vaginal swab Copan eSwab TE buffer −80 °C
Dacron swab Protease inhibitor −80 °C
Placenta, fetal membranes and cord No treatment Peripheral biopsies Snap frozen
Central biopsies Snap frozen
Peripheral biopsies Paraffin embedding
Central biopsies Paraffin embedding
Cord tissue Snap frozen
Cord tissue Paraffin embedding
Membrane Paraffin embedding
Heel prick No treatment Blood spot Room temperature
Neonatal stool DNA/RNA Shield tube Swab −80 °C
Table 3 Overview of type of biological samples & the collection schedule
Time of sample collection Type of biological sample
PRECISE visit 1 Maternal blood, urine, mid-vaginal swabs
PRECISE visit 2 (≥28+ 0 weeks) Maternal blood and urine
Intrapartum (at the onset of labour) Maternal mid-vaginal swab
Delivery Umbilical cord blood, placenta and cord tissue, placental membranes
Within 48 h post-partum Newborn heel prick only if cord blood is not collected (only The Gambia and Mozambique),
maternal blood and urine.
Post-partum visit (6 weeks after delivery) Neonatal stool sample, maternal blood and urine. Neonatal heel prick (if required, Kenya only)
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written feedback. This may action site visits or
additional quality control measures.
 Controlling access to the PRECISE samples and data
including reviewing applications for samples. The
PRECISE Study Sample Request Form will be
provided to all interested parties. The form requires
details of the scientific rationale, justification of the
requested sample numbers and volume (including
power calculations), data fields required from the
PRECISE data dictionary and a data analysis plan.
The form requires one of the PRECISE PIs to be a
co-applicant on the proposed study. The proposed
study will be reviewed for scientific merit, scientific
priority according to the PRECISE aims, overlap
with previously agreed studies and for sample
availability.
 Ensuring samples and data are shared in with the
consent received and the data and sample transfer
agreements arranged between institutions. This
includes forming a collaborative group of the
technology transfer officers from each of the
countries to facilitate sample and data transfer and
avoid unnecessary delay.
 Establishing policies for the long-term sustainability
and utilisation of the biorepository.
Results
Barriers encountered in developing the biorepository
Several challenges were overcome whilst setting up the
biorepository. After site visits from the team to scope
out the available resources and facilities, several issues
and considerations were identified. These are described
below.
Capacity building
Facilities: As anticipated, nearly all the rural sites re-
quired renovations to their facilities prior to study com-
mencement. In The Gambia, the new field sites required
significant work to renovate existing facilities including
an external storage room for the liquid nitrogen equip-
ment in the main hospital, building a laboratory in one
of the rural clinics and refurbishing the laboratory in the
second rural clinic. In Kenya, in the rural clinic, the la-
boratory had to be extended to provide the required
space. In Mozambique, the rural site also required reno-
vation work on the laboratory. This incurred significant
costs, some unanticipated due to locally poor infrastruc-
ture. This has benefited sites greatly as these improve-
ments to the laboratory infrastructure will inevitably
contribute to improved patient care as well as enabling a
new population to become engaged in research.
Staffing: Co-ordinating the timing of staff recruit-
ment to a multi-centre study of this size was challen-
ging. In some sites we faced delays in hiring key staff
(e.g., data managers and laboratory technicians) pri-
marily because staff were needed for specialised roles
with a limited pool of suitable candidates. Most of the
staff were recruited directly to the study with a minor-
ity being seconded from an existing post. In some in-
stances, budget allocations had to be exceeded in order
to recruit staff with the requisite qualifications and
training. Staff turnover resulted in additional chal-
lenges before the launch; including site co-ordinator,
laboratory manager and data manager posts. However,
with additional support and training, all teams were in
place by the start date to ensure smooth delivery of the
study.
Fig. 1 Placenta processing protocol – the figure illustrates where the samples from the placenta tissue, membranes and cord are collected
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Training: None of the field sites participating in the
study had experience of such an extensive collection of
biospecimens. The field staff required training in sample
collection, processing, and storage and the PRECISE
Baobab laboratory information management system
(LIMS), (https://baobablims.org/). As many of the staff
were not experienced in working in laboratories, all staff
had to complete good clinical practice (GCP) and good
clinical laboratory practice (GCLP) courses and liquid
nitrogen training to ensure safety in the laboratory. This
training was facilitated by The Global Health Network
(https://tghn.org), which hosts short courses online in
clinical research to facilitate high-quality research. We
used the train-the-trainer model, where in a central
training session held in The Gambia, the laboratory
leads from each site were trained in sample collection
and processing. These staff then trained all the staff in
their site in their local language where the teams had ac-
cess to the SOPs, instructions and forms in their local
language. The biobanking lead visited each site prior to
commencement of the study and will visit again within
6 months following the start of recruitment to provide
any necessary further training and solve any issues.
Reinforcement training will be delivered via online webi-
nars, online conferencing and further site visits.
The PRECISE PIs are also committed to capacity
building to enable training of scientists and bioinforma-
ticians in the African countries to enable the acquisition
of the necessary skill base to undertake local analysis of
the biorepository samples. Whilst not included in the
original funding application, ongoing funding applica-
tions include provision for these activities.
Cultural barriers: Community engagement is critical
to gaining local acceptance and enthusiasm for the pro-
ject. This has started in each site through meetings with
local community leaders, healthcare professionals, reli-
gious leaders and institutional leaders as well as meet-
ings with women and their families in each local
community. From the work done so far, we have found,
for example, that there is resistance to blood sampling in
pregnancy over and above that needed for routine clin-
ical care, as it is perceived too much blood is being col-
lected. This issue has been raised by field workers and
clinical staff as well as by women being recruited, and
other community members. To overcome this, extensive
training of the field workers and nurses was undertaken
to educate and inform them that the volumes required
are not harmful. This training will continue throughout
the study. The collection of the placenta was also a new
concept to many of these communities, especially where
women take the placenta home after delivery. Again, this
concern was, and will continue to addressed through
education and community engagement. In one of the
countries, taking blood from the newborn before leaving
the facility was considered to be stigmatising to the fam-
ily as this is typically limited to the infants of HIV-
positive women. For that reason, the protocol was modi-
fied so that in cases where the cord blood collection was
either refused or missed, a heel prick will be performed
at the 6 week postpartum visit. The breastfeeding ques-
tions had to be well phrased to avoid any HIV implica-
tions. HIV-positive mothers are sensitive to being asked
if they are breastfeeding due to perceptions linking bot-
tle feeding with HIV-positive status. Extensive training
was done to ensure staff are sensitive in their approach
and questions are so phrased that women did not feel
stigmatised.
Procurement: In recognition of purchasing power of
bulk buying, most consumables (excluding liquids) and
equipment were ordered by the central co-ordinating
team and shipped to the sites. Whilst this ensured
consistency in materials, despite suppliers’ intentions,
shipping was often delayed mainly due to stock issues,
especially for custom-made items (freezer racking, liquid
nitrogen generators) or where large orders were placed
(blood spot cards).
Shipments and taxes: Discussions were held with all
sites prior to commencement of the study regarding im-
portation of essential laboratory consumables and equip-
ment and the necessary procedures included in the
study planning. However, some local and unanticipated
delays were incurred. In Kenya, for example, recently
implemented importation regulations requires an inspec-
tion of goods being sent to obtain a shipping permit be-
fore leaving the country of origin. Introduced recently, a
permit from the Pharmacy and Poisons Board and the
Energy Regulatory Commission was needed for -80 °C
freezers. As this process was not yet streamlined, this led
to a delay of 6 months for freezer importation. Although
anticipated, import taxes in Mozambique were ≥ 50% of
the value of the goods but, once paid, the importation
process was relatively straightforward.
Baobab LIMS customisation: The PRECISE bioreposi-
tories use the web-based Baobab LIMS sample tracking.
The Baobab LIMS was developed by African and Euro-
pean researchers as an open-source LIMS to help har-
monise biobanks across Africa. Each country hosts their
own database on their servers ensuring each site only
has access to their own data. Access to the database is
restricted by username and password. Establishing the
database, programming the database and staff training
incurred some minor delays. Despite this, the PRECISE
team remain very supportive of an open-source sample
solution resource for Africa.
Sample storage: Several of the sites do not have a reli-
able electricity connection making − 80 °C freezers less
attractive. As an alternative, liquid nitrogen (LN2) was
considered; however dependable sources were not always
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available. To circumvent these issues liquid nitrogen
generators were purchased for sites in The Gambia and
Mozambique. Samples are stored in LN2 tanks tempor-
arily in the field before being moved to − 80 °C freezers
at the main biobanking facilities, which have reliable
electricity. For Kenya, where freezers were installed,
freezer alarm systems were put in place. Due to paucity
of reliable in-country biorepositories, one of the chal-
lenges faced was finding suitable off site back up biore-
positories to enable split sample storage or transfer of
samples in the event the primary storage failed. Rather,
each site has a stringent plan in the event that a sample
storage unit fails: this includes back-up power supplies
for freezers and spare storage space in alternative units.
For example, in the event of a power failure, all freezers
have a site specific alarm system including mobile phone
alerts.
Work flow processes
A number of processes were built into the PRECISE
work flow to ensure quality samples are obtained and to
minimise any errors. These include:
Participant ID numbers: Each participant identification
number is unique and contains a ‘check digit’ to detect
any errors in data entry. This check digit will detect
any single digit errors or any adjacent transposition
errors. This check digit, in combination with the ID
being in a 2D barcode which can be scanned, should
minimise the risk of any data or samples being linked
to the wrong participant. These ID numbers are
generated by the central data management team and
are used to link the clinical data to the biological
sample data which are stored in separate databases.
Kit building: To help with the sample collection
process, sample collection kits are prepared by each
site. These kits all have a unique kit number and
contain all the required consumables for sample
collection and processing. The sample aliquots are
assigned a unique sample identification number which
is linked to the kit ID number. The sample IDs are
printed on the sample storage tubes using thermal
printing technology. The printed text is resistant to
alcohol, water, liquid nitrogen and mechanical abrasion
and is stable over a wide temperature range making it
durable. During the kit building process, the final step,
for QC purposes, is to weigh the kit. If the weight is
not as expected, the kit contents can be checked to
ensure all the required consumables are present.
Discussion
Biobanking is becoming increasingly recognised and uti-
lised in Africa in a variety of fields including stroke [7],
oncology [8], infectious disease [9] and pregnancy. This
summary represents a practical account of the necessary
stages required in setting up a large multi-country biore-
pository and database in low income settings. Whilst con-
fined to three sub-Saharan African countries, the issues
covered will be translatable to other countries in similar
settings and, it is hoped will serve as a useful guide for
others contemplating a study of similar complexity.
To ensure that PRECISE sites may participate in future
collaborations and consortia, specimen collection has
been designed to be harmonised with other similar large
pregnancy cohort studies such as AMANHI [10],
INTERBIO-21st [11], GAPPS [12] and HeLTI [13]. The
PRECISE Network is also aligned with H3Africa goals
[3] by building on existing infrastructure and resources
to develop a cohort of African scientists focussed on sig-
nificant global health problems that disproportionately
affect women and families in sub-Saharan Africa.
Facilities and sample storage: The need to build spe-
cific facilities to house the scientific equipment and
renovate laboratories led to unanticipated costs and time
to setting up the repository; therefore, we recommend
that ample contingency funding is included in any future
applications for similar studies.
Staffing: Whilst central research management are keen
to appoint site staff and avoid delays in initiating recruit-
ment, there is also the potential in having a full team in
place too early due to other unforeseen infrastructure is-
sues which can delay the commencement of the study.
This can lead to unnecessary staff costs and insufficient
work in the team in the set-up phase. As in accordance
with best practice, we planned to phase recruitment by
starting recruitment in each country sequentially. From
our experience, a phased recruitment process of staff
within each centre might also be considered, starting
with the core team and expanding to the field teams
once timelines are in place.
Training: From our experience, regular contact and
training with sites is essential to ensure compliance with
SOPs and to pre-empt local deviations. Engaging with
the site teams regularly boosts morale and keeps the
teams motivated; this is essential when asking teams to
process multiple samples according to a strict SOP. The
PRECISE Annual Meetings have been proven to be ex-
cellent team building exercises with very positive feed-
back and should be preserved as a fundamental element
of large research projects.
Cultural: Overcoming the cultural barriers to setting
up this study, a planned activity, proved to be a vi-
tally important activity of the programme which is
not always included in project design. It is known
that support from the communities reduces the chal-
lenges to such a complex endeavour [14], therefore
extensive engagement with all levels of the commu-
nity has been, and will continue to be, done to help
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in breaking down these barriers. For example, the
anxiety about the volume of blood being taken was
dispelled in The Gambia by demonstration of the ac-
tual volume using teaspoons. Being aware of cultural
issues and developing systems to work around them
is a pre-requisite for ongoing community support.
Procurement, Shipments and Taxes: Retrospectively,
we would recommend purchase of consumables goods
readily available in country and confine external pur-
chasing to equipment and consumables not available lo-
cally. However, it must be recognised that sophisticated
storage equipment is often not accessible and time is
well spent in reviewing local availability of equipment
and supplies. Given our experience, we advise that ad-
equate time is built in to engage site teams early in the
procurement process to identify and navigate local regu-
lations and challenges so that the receipt of goods into
their countries may be streamlined as much as possible.
In conclusion, the PRECISE project presented challenges
but has proven the feasibility of setting up a complex biore-
pository in associate with a detailed clinical database. Devel-
opment of the project was greatly facilitated by the
inclusion of a highly experienced multi-disciplinary team
and the early development of structured management sys-
tem devolved to specialised groups. Everything is now in
place for the implementation of the biorepository and the
governance of it use as a shared resource.
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